Co-Founder and CEO of Gramics Bio. Building the non-viral delivery platform to unlock DNA-based therapeutics
London
Joined August 2011
- Tweets9.1K
- Following187
- Followers1.8K
- Likes18K
Pinned Tweet
Proud to have co-authored this @JournalofCF editorial on opportunities for #MachineLearning to inform clinical decisions and make life easier for people with #cysticfibrosis:
cysticfibrosisjournal.com/ar… #openaccess
7/7: As CBO, I’ll be responsible for corporate strategy, funding, business development and strategic partnerships.
Drop me a DM if you’d like to find out more about our exciting plans.
3
2
201
6/7: Excited to bring my experience in CF drug development and draw from my broader background in investment banking, venture building and business development to help turn Panthura’s exciting technology into transformative treatments.
89
5/7: Beyond CF as the initial target, the technology has potential applications in the treatment of other serious genetic diseases including Primary Ciliary Dyskinesia and Surfactant Lung Disorders.
91
4/7: The company’s non-viral nanoparticles are designed for targeted DNA delivery via the bloodstream to overcome the challenges of delivering gene therapy to epithelial cells in the lungs.
In vivo proof of concept studies are currently underway.
70
3/7: While Panthura was set up to solve the challenge of delivering nucleic acid based therapeutics in CF, initially targeting the 10-15% of patients who cannot benefit from CFTR modulators, its technology has applications beyond CF.
65
2/7: The company was founded in June 2024 by Dr Alice Preston (formerly of Ochre Bio) and Dr Duygu Yilmaz (Ochre Bio, ProQR), two brilliant scientific entrepreneurs with backing from @deepsciventures and @CF_Foundation’s venture investment arm.
189
I’m excited to join Panthura as Chief Business Officer.
Panthura is developing next generation genetic therapies for cystic fibrosis and other serious genetic diseases.
1/7
5
90
Oli Rayner retweeted
🚀What we're looking forward to:
@DesciLondon in January of 2023 is fast approaching! Vibe Bio, along with CEO, @aloktayi will present a keynote talk and rare disease workshop in collaboration with @svennj, @eperlste, & @oli_rayner.
See you there!
desci.london/?utm_campaign=V…
Biases, barriers and bottlenecks in research funding, IP, data sharing and publication means good science goes unfunded.
#DeSci brings community-driven ideas, mechanisms and tools to change that.
Come to @DesciLondon to find out more and get involved.
#RareDisease
It is with great excitement that we can officially announce DeSci London 2023! 🎉The event will take place over January 15-16 hosted @TheCrick. Please visit DeSci.London/ for tickets, speaker applications and more.
1
We think this is a first: we took patient-driven research priorities and developed them into testable trial hypotheses in a collaborative virtual process involving people with #cysticfibrosis and healthcare professionals #coproduction
sciencedirect.com/science/ar… via @JournalofCF
Exciting @CF_Foundation deal with @FlagshipPioneer with up to $110M to accelerate development of genetic-based therapies for everyone with CF regardless of mutation. New CF-focused company will feed off the best tech and innovation in Flagship portfolio:
cff.org/About-Us/Media-Cente…
3
Oli Rayner retweeted
EE is conducting a survey about the “final 10%” of the CF community that does not benefit from currently available CFTR modulators. If you’re part of the final 10%, your input is critical! TAKE THE SURVEY >> surveymonkey.com/r/thefinal1…
Oli Rayner retweeted
If you have broad technical knowledge in gene therapy, cell therapy, cellular engineering or synthetic biology & have an interest in science commercialisation, with the dream of building your own company, we would love to hear from you! cc @CF_Foundation
deepscienceventures.com/cure…
Proud to have played a small part in this exciting collaboration between @CF_Foundation and London's @deepsciventures to unlock new approaches to genetic therapies for people with #cysticfibrosis:
cff.org/About-Us/Media-Cente… #CFWeek #untilitsdone
If you have cystic fibrosis and 5 mins, this could have a real impact....'Target Product Profile' means if you could wave a magic wand and have the perfect new treatment for infections, what would it look like? It could be about the target infection or user-friendliness
ONLY 1 WEEK TO GO ⏰
Have your say to help shape future medicines for #CysticFibrosis infections.
Complete our short survey today to let us know if we reflected your needs and priorities in our TPPs 👇
ow.ly/Su0B50E0YHJ @cftrust
2
Clear recommendation and advice today for lung transplant recipients in relation to Pfizer/BioNTech C-19 vaccine from @RBandH:
rbht.nhs.uk/our-services/lun…
No silent night. . .
Looking forward to @cftrust's virtual Carols by Candlelight tonight 7-8pm
Singing: Winchester College Chapel Choir
Speaking: Judi Dench, Damian Lewis ++
Tickets: £10/device
Christmas Jumpers: optional
cysticfibrosis.org.uk/get-in…
🥳🎤🥳
Unbelievable this costs $35 to access:
"Environmental risks of P. aeruginosa: what to advise patients and parents" @JournalofCF
cysticfibrosisjournal.com/ar…
Particularly as it references a @BMJ_Open paper we wrote on patient perspective and paid the fee to make our paper #openaccess
2
1
The @CF_Foundation and international partners like @cftrust are lazer-focused on finding effective therapies for people who won't benefit from CFTR modulators and more curative options for everyone with #cysticfibrosis
Our latest Guest Blog is by @oli_rayner of @CF_Foundation, who explains how the Cystic Fibrosis Foundation's Path to a Cure Programme accelerates genetic-based treatments for CF.
Find out how you can get involved👇
bioindustry.org/news-listing…
